Biotechnology Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors – Candel Therapeutics (NASDAQ:CADL) Read more
Biotechnology Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer – Candel Therapeutics (NASDAQ:CADL) Read more
